Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Cardiovascular Diseases | 47 | 2024 | 15398 | 2.870 |
Why?
|
Cost-Benefit Analysis | 32 | 2023 | 5483 | 2.480 |
Why?
|
Amyloid Neuropathies, Familial | 5 | 2024 | 150 | 2.280 |
Why?
|
Drug Costs | 11 | 2023 | 1179 | 2.260 |
Why?
|
Hypercholesterolemia | 9 | 2024 | 1141 | 1.870 |
Why?
|
Hypolipidemic Agents | 5 | 2023 | 609 | 1.840 |
Why?
|
American Heart Association | 19 | 2024 | 1039 | 1.780 |
Why?
|
Benzoxazoles | 4 | 2024 | 89 | 1.760 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 12 | 2024 | 3223 | 1.590 |
Why?
|
Anticholesteremic Agents | 6 | 2019 | 965 | 1.520 |
Why?
|
Primary Prevention | 9 | 2024 | 1185 | 1.480 |
Why?
|
Endocarditis | 5 | 2022 | 349 | 1.360 |
Why?
|
Heart Failure | 17 | 2024 | 11595 | 1.290 |
Why?
|
Health Expenditures | 10 | 2023 | 2342 | 1.200 |
Why?
|
Proprotein Convertases | 3 | 2016 | 95 | 1.160 |
Why?
|
Phenprocoumon | 2 | 2015 | 20 | 0.980 |
Why?
|
Acenocoumarol | 2 | 2015 | 19 | 0.980 |
Why?
|
Hyperlipoproteinemia Type II | 5 | 2024 | 393 | 0.970 |
Why?
|
Medicare | 24 | 2023 | 6724 | 0.960 |
Why?
|
Quality-Adjusted Life Years | 12 | 2022 | 1722 | 0.930 |
Why?
|
Antihypertensive Agents | 8 | 2024 | 2018 | 0.930 |
Why?
|
Acute Coronary Syndrome | 6 | 2021 | 2181 | 0.920 |
Why?
|
Dyslipidemias | 2 | 2023 | 867 | 0.920 |
Why?
|
Specialty Boards | 2 | 2016 | 235 | 0.900 |
Why?
|
Inflation, Economic | 1 | 2023 | 28 | 0.900 |
Why?
|
Ticlopidine | 4 | 2015 | 730 | 0.860 |
Why?
|
United States | 73 | 2024 | 71902 | 0.850 |
Why?
|
Hypertension | 12 | 2024 | 8502 | 0.830 |
Why?
|
Cost of Illness | 4 | 2024 | 1925 | 0.800 |
Why?
|
Cholesterol, LDL | 9 | 2024 | 2375 | 0.800 |
Why?
|
Atherosclerosis | 8 | 2024 | 3401 | 0.780 |
Why?
|
Endocarditis, Bacterial | 2 | 2022 | 442 | 0.760 |
Why?
|
Aortic Valve Stenosis | 7 | 2023 | 2002 | 0.710 |
Why?
|
Costs and Cost Analysis | 2 | 2016 | 1668 | 0.690 |
Why?
|
Humans | 168 | 2024 | 757566 | 0.690 |
Why?
|
Vital Signs | 1 | 2021 | 144 | 0.680 |
Why?
|
Diabetes Mellitus | 7 | 2024 | 5815 | 0.670 |
Why?
|
Health Care Costs | 7 | 2024 | 3234 | 0.670 |
Why?
|
Coronary Disease | 11 | 2024 | 5915 | 0.660 |
Why?
|
Platelet Aggregation Inhibitors | 4 | 2015 | 2744 | 0.660 |
Why?
|
Rare Diseases | 1 | 2024 | 618 | 0.640 |
Why?
|
Pericarditis | 1 | 2020 | 134 | 0.630 |
Why?
|
Internal Medicine | 2 | 2016 | 1048 | 0.620 |
Why?
|
Blood Pressure | 9 | 2024 | 8453 | 0.610 |
Why?
|
Forecasting | 2 | 2024 | 2919 | 0.610 |
Why?
|
Cardiomyopathies | 2 | 2020 | 1945 | 0.610 |
Why?
|
Climate Change | 1 | 2024 | 485 | 0.600 |
Why?
|
Stroke | 11 | 2024 | 9695 | 0.590 |
Why?
|
Postoperative Hemorrhage | 3 | 2023 | 412 | 0.560 |
Why?
|
Ownership | 1 | 2019 | 339 | 0.550 |
Why?
|
Warfarin | 3 | 2021 | 1483 | 0.550 |
Why?
|
Glucosides | 1 | 2021 | 498 | 0.550 |
Why?
|
Atrial Fibrillation | 6 | 2023 | 5105 | 0.530 |
Why?
|
Health Services | 1 | 2021 | 752 | 0.520 |
Why?
|
Policy Making | 1 | 2019 | 538 | 0.520 |
Why?
|
Ventricular Dysfunction, Left | 2 | 2023 | 2115 | 0.510 |
Why?
|
Computers, Handheld | 1 | 2017 | 209 | 0.510 |
Why?
|
Medicare Part D | 4 | 2023 | 353 | 0.500 |
Why?
|
Health Status Disparities | 3 | 2021 | 1821 | 0.500 |
Why?
|
Coronary Artery Bypass | 6 | 2022 | 2188 | 0.500 |
Why?
|
Cardiovascular Agents | 1 | 2021 | 839 | 0.490 |
Why?
|
Stroke Volume | 5 | 2023 | 5461 | 0.490 |
Why?
|
Secondary Prevention | 6 | 2024 | 1474 | 0.490 |
Why?
|
Antibodies, Monoclonal | 5 | 2017 | 9163 | 0.480 |
Why?
|
Benzhydryl Compounds | 1 | 2021 | 900 | 0.470 |
Why?
|
Protease Inhibitors | 1 | 2018 | 753 | 0.470 |
Why?
|
Randomized Controlled Trials as Topic | 6 | 2023 | 10135 | 0.450 |
Why?
|
Anti-Bacterial Agents | 3 | 2023 | 7399 | 0.440 |
Why?
|
Anticoagulants | 6 | 2023 | 4777 | 0.440 |
Why?
|
Adenosine | 2 | 2015 | 802 | 0.430 |
Why?
|
Coronary Artery Disease | 8 | 2024 | 6364 | 0.420 |
Why?
|
Genotype | 4 | 2023 | 12951 | 0.400 |
Why?
|
Defibrillators, Implantable | 1 | 2022 | 1487 | 0.400 |
Why?
|
Angina Pectoris | 2 | 2016 | 959 | 0.400 |
Why?
|
Influenza, Human | 1 | 2023 | 1516 | 0.400 |
Why?
|
Heart Valve Prosthesis Implantation | 4 | 2023 | 1547 | 0.400 |
Why?
|
Nutrition Surveys | 7 | 2024 | 1716 | 0.390 |
Why?
|
Aged | 48 | 2024 | 167890 | 0.390 |
Why?
|
Public Facilities | 1 | 2011 | 35 | 0.390 |
Why?
|
Respiratory Insufficiency | 1 | 2020 | 1230 | 0.380 |
Why?
|
Environmental Exposure | 2 | 2024 | 4411 | 0.380 |
Why?
|
Cardiology | 4 | 2023 | 1667 | 0.380 |
Why?
|
Cost Sharing | 3 | 2020 | 409 | 0.360 |
Why?
|
Drug Therapy, Combination | 6 | 2023 | 6292 | 0.360 |
Why?
|
Mass Screening | 3 | 2023 | 5412 | 0.360 |
Why?
|
Cardiovascular System | 1 | 2018 | 835 | 0.360 |
Why?
|
Myocardial Infarction | 8 | 2024 | 11422 | 0.340 |
Why?
|
Heart Diseases | 4 | 2024 | 2781 | 0.340 |
Why?
|
Risk Assessment | 7 | 2024 | 23816 | 0.340 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 2 | 2008 | 1503 | 0.340 |
Why?
|
Medical Oncology | 1 | 2021 | 2308 | 0.330 |
Why?
|
Rheumatic Heart Disease | 2 | 2020 | 165 | 0.330 |
Why?
|
Health Services Accessibility | 3 | 2023 | 5382 | 0.320 |
Why?
|
HIV Infections | 7 | 2021 | 17270 | 0.310 |
Why?
|
Comparative Effectiveness Research | 2 | 2013 | 707 | 0.310 |
Why?
|
Hemorrhage | 4 | 2023 | 3399 | 0.300 |
Why?
|
Male | 65 | 2024 | 358180 | 0.300 |
Why?
|
Insulin | 1 | 2022 | 6578 | 0.300 |
Why?
|
Female | 69 | 2024 | 389943 | 0.300 |
Why?
|
Population Surveillance | 2 | 2017 | 2599 | 0.290 |
Why?
|
Medical Informatics | 1 | 2015 | 732 | 0.290 |
Why?
|
Patient Readmission | 5 | 2023 | 3241 | 0.290 |
Why?
|
Artifacts | 1 | 2016 | 1894 | 0.290 |
Why?
|
Adult | 42 | 2024 | 219725 | 0.280 |
Why?
|
Patient Care Planning | 1 | 2013 | 906 | 0.280 |
Why?
|
Myocardial Ischemia | 3 | 2023 | 2109 | 0.280 |
Why?
|
Anti-HIV Agents | 2 | 2021 | 4502 | 0.280 |
Why?
|
Telemedicine | 4 | 2021 | 3013 | 0.280 |
Why?
|
Aspirin | 4 | 2023 | 3128 | 0.280 |
Why?
|
Mortality | 4 | 2021 | 2882 | 0.280 |
Why?
|
India | 5 | 2020 | 2328 | 0.270 |
Why?
|
Developed Countries | 2 | 2024 | 440 | 0.270 |
Why?
|
Risk Factors | 27 | 2024 | 73708 | 0.270 |
Why?
|
Middle Aged | 48 | 2024 | 219192 | 0.270 |
Why?
|
Crowding | 2 | 2017 | 142 | 0.260 |
Why?
|
Angioplasty, Balloon, Coronary | 1 | 2012 | 1731 | 0.240 |
Why?
|
Barbering | 2 | 2021 | 9 | 0.240 |
Why?
|
Treatment Outcome | 20 | 2023 | 64242 | 0.240 |
Why?
|
Algorithms | 3 | 2022 | 13952 | 0.240 |
Why?
|
Drug Combinations | 3 | 2019 | 2020 | 0.240 |
Why?
|
Fatty Acids | 2 | 2023 | 1803 | 0.230 |
Why?
|
Thiazolidinediones | 1 | 2007 | 461 | 0.230 |
Why?
|
Registries | 7 | 2022 | 8164 | 0.230 |
Why?
|
Income | 2 | 2024 | 1867 | 0.220 |
Why?
|
Aged, 80 and over | 21 | 2022 | 58558 | 0.220 |
Why?
|
Decision Support Techniques | 4 | 2019 | 1991 | 0.220 |
Why?
|
Minority Groups | 4 | 2024 | 1199 | 0.220 |
Why?
|
Practice Guidelines as Topic | 8 | 2024 | 7366 | 0.210 |
Why?
|
Lipids | 3 | 2023 | 3326 | 0.210 |
Why?
|
Serine Endopeptidases | 3 | 2016 | 1020 | 0.210 |
Why?
|
Aftercare | 3 | 2023 | 909 | 0.210 |
Why?
|
Delivery of Health Care | 3 | 2017 | 5325 | 0.210 |
Why?
|
Tetrazoles | 2 | 2019 | 899 | 0.210 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3077 | 0.200 |
Why?
|
Angina, Unstable | 2 | 2019 | 888 | 0.200 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3197 | 0.200 |
Why?
|
Aortic Valve | 5 | 2023 | 1950 | 0.200 |
Why?
|
Pharmacists | 2 | 2021 | 258 | 0.200 |
Why?
|
Healthcare Disparities | 3 | 2022 | 3317 | 0.190 |
Why?
|
Hypoglycemic Agents | 2 | 2020 | 3069 | 0.190 |
Why?
|
Viridans Streptococci | 1 | 2021 | 16 | 0.190 |
Why?
|
Rehabilitation Centers | 1 | 2023 | 247 | 0.190 |
Why?
|
Substance-Related Disorders | 3 | 2023 | 4404 | 0.190 |
Why?
|
Subtilisins | 1 | 2021 | 81 | 0.190 |
Why?
|
Dicarboxylic Acids | 1 | 2021 | 77 | 0.190 |
Why?
|
Pandemics | 6 | 2023 | 8600 | 0.180 |
Why?
|
Ozone | 1 | 2024 | 477 | 0.180 |
Why?
|
Eligibility Determination | 1 | 2024 | 419 | 0.180 |
Why?
|
Disasters | 1 | 2006 | 517 | 0.180 |
Why?
|
Disaster Planning | 1 | 2006 | 557 | 0.180 |
Why?
|
Electronics | 1 | 2022 | 315 | 0.180 |
Why?
|
Cohort Studies | 11 | 2024 | 41190 | 0.180 |
Why?
|
Antibiotic Prophylaxis | 2 | 2022 | 640 | 0.180 |
Why?
|
Hospitals, Rural | 1 | 2022 | 174 | 0.170 |
Why?
|
Computer Simulation | 3 | 2019 | 6198 | 0.170 |
Why?
|
Cocaine-Related Disorders | 1 | 2023 | 461 | 0.170 |
Why?
|
California | 3 | 2019 | 1418 | 0.170 |
Why?
|
Markov Chains | 2 | 2021 | 965 | 0.170 |
Why?
|
Hospitals, Urban | 1 | 2022 | 500 | 0.170 |
Why?
|
Housing | 2 | 2023 | 666 | 0.170 |
Why?
|
Catheter Ablation | 1 | 2013 | 2741 | 0.170 |
Why?
|
Rural Health | 1 | 2021 | 296 | 0.170 |
Why?
|
Dental Care | 1 | 2022 | 278 | 0.170 |
Why?
|
Medicaid | 3 | 2022 | 2794 | 0.160 |
Why?
|
Marketing | 1 | 2021 | 220 | 0.160 |
Why?
|
Quality of Life | 2 | 2020 | 13263 | 0.160 |
Why?
|
Prealbumin | 1 | 2020 | 222 | 0.160 |
Why?
|
Budgets | 1 | 2020 | 229 | 0.160 |
Why?
|
Adrenergic beta-Antagonists | 2 | 2014 | 1240 | 0.160 |
Why?
|
Hyperlipidemias | 1 | 2023 | 771 | 0.160 |
Why?
|
Tricuspid Valve Insufficiency | 1 | 2022 | 353 | 0.160 |
Why?
|
Prescriptions | 1 | 2021 | 386 | 0.160 |
Why?
|
Protective Devices | 1 | 2018 | 72 | 0.160 |
Why?
|
Urban Health | 1 | 2021 | 533 | 0.150 |
Why?
|
Prisoners | 1 | 2022 | 314 | 0.150 |
Why?
|
Cholesterol, HDL | 1 | 2005 | 1809 | 0.150 |
Why?
|
Cocaine | 1 | 2023 | 958 | 0.150 |
Why?
|
Retrospective Studies | 19 | 2023 | 79984 | 0.150 |
Why?
|
Models, Statistical | 5 | 2020 | 5068 | 0.150 |
Why?
|
Aerospace Medicine | 1 | 2018 | 95 | 0.150 |
Why?
|
Nitroglycerin | 1 | 2019 | 328 | 0.150 |
Why?
|
Holidays | 1 | 2017 | 41 | 0.150 |
Why?
|
Patient Discharge | 4 | 2023 | 3428 | 0.150 |
Why?
|
Economics, Medical | 1 | 2017 | 112 | 0.140 |
Why?
|
Common Cold | 1 | 2017 | 63 | 0.140 |
Why?
|
Hinduism | 1 | 2016 | 14 | 0.140 |
Why?
|
Brain Ischemia | 2 | 2022 | 3047 | 0.140 |
Why?
|
Mexico | 1 | 2019 | 758 | 0.140 |
Why?
|
Legislation, Drug | 1 | 2019 | 214 | 0.140 |
Why?
|
Death, Sudden | 1 | 2018 | 302 | 0.140 |
Why?
|
State Government | 1 | 2019 | 381 | 0.140 |
Why?
|
Mucocutaneous Lymph Node Syndrome | 1 | 2021 | 537 | 0.140 |
Why?
|
Nigeria | 1 | 2019 | 762 | 0.130 |
Why?
|
Biphenyl Compounds | 2 | 2019 | 988 | 0.130 |
Why?
|
Hospital Costs | 2 | 2020 | 949 | 0.130 |
Why?
|
Nebulizers and Vaporizers | 1 | 2017 | 137 | 0.130 |
Why?
|
Rural Population | 3 | 2022 | 2253 | 0.130 |
Why?
|
Epidemics | 2 | 2019 | 512 | 0.130 |
Why?
|
Troponin I | 1 | 2020 | 632 | 0.130 |
Why?
|
Heart Valve Prosthesis | 2 | 2022 | 1466 | 0.130 |
Why?
|
Shock, Cardiogenic | 1 | 2021 | 707 | 0.130 |
Why?
|
Cross-Sectional Studies | 8 | 2024 | 25924 | 0.130 |
Why?
|
Thrombocytopenia | 1 | 2023 | 1174 | 0.130 |
Why?
|
Prescription Drugs | 1 | 2023 | 626 | 0.130 |
Why?
|
Follow-Up Studies | 9 | 2022 | 39020 | 0.130 |
Why?
|
United States Department of Veterans Affairs | 1 | 2020 | 907 | 0.130 |
Why?
|
Adrenergic beta-Agonists | 1 | 2017 | 344 | 0.130 |
Why?
|
Patient Acceptance of Health Care | 2 | 2019 | 3165 | 0.130 |
Why?
|
Cause of Death | 4 | 2021 | 3667 | 0.120 |
Why?
|
Data Mining | 1 | 2020 | 551 | 0.120 |
Why?
|
Education, Medical, Continuing | 1 | 2020 | 824 | 0.120 |
Why?
|
Troponin T | 1 | 2020 | 761 | 0.120 |
Why?
|
Electrocardiography | 3 | 2021 | 6363 | 0.120 |
Why?
|
Myocardial Revascularization | 1 | 2019 | 792 | 0.120 |
Why?
|
Marijuana Abuse | 1 | 2019 | 410 | 0.120 |
Why?
|
Clinical Laboratory Techniques | 1 | 2020 | 747 | 0.120 |
Why?
|
Prevalence | 6 | 2024 | 15640 | 0.120 |
Why?
|
Medical Audit | 1 | 2016 | 452 | 0.120 |
Why?
|
Hospital Mortality | 4 | 2022 | 5243 | 0.120 |
Why?
|
Smoking | 1 | 2011 | 9036 | 0.120 |
Why?
|
Dogs | 1 | 2019 | 3838 | 0.120 |
Why?
|
Reimbursement Mechanisms | 1 | 2020 | 663 | 0.120 |
Why?
|
Neoplasms | 2 | 2021 | 21986 | 0.120 |
Why?
|
Employment | 1 | 2021 | 1112 | 0.120 |
Why?
|
Public Health Practice | 1 | 2016 | 218 | 0.120 |
Why?
|
Direct Service Costs | 1 | 2014 | 59 | 0.120 |
Why?
|
Cerebrovascular Disorders | 1 | 2021 | 1475 | 0.120 |
Why?
|
South Africa | 1 | 2019 | 1822 | 0.110 |
Why?
|
Outpatients | 1 | 2022 | 1590 | 0.110 |
Why?
|
Drugs, Generic | 2 | 2021 | 444 | 0.110 |
Why?
|
Clinical Trials as Topic | 4 | 2021 | 7982 | 0.110 |
Why?
|
Cough | 1 | 2017 | 594 | 0.110 |
Why?
|
China | 1 | 2019 | 2336 | 0.110 |
Why?
|
Reminder Systems | 1 | 2016 | 387 | 0.110 |
Why?
|
Bayes Theorem | 1 | 2021 | 2318 | 0.110 |
Why?
|
Patient Transfer | 1 | 2020 | 774 | 0.110 |
Why?
|
Arthroplasty, Replacement, Knee | 1 | 2023 | 1369 | 0.110 |
Why?
|
Mitral Valve Insufficiency | 1 | 2022 | 1401 | 0.110 |
Why?
|
Urinary Tract Infections | 1 | 2019 | 806 | 0.110 |
Why?
|
Heart Rate | 2 | 2014 | 4172 | 0.110 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2019 | 1016 | 0.110 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 1 | 2014 | 244 | 0.100 |
Why?
|
Drug Administration Schedule | 3 | 2021 | 4845 | 0.100 |
Why?
|
Medically Underserved Area | 1 | 2015 | 257 | 0.100 |
Why?
|
Proliferating Cell Nuclear Antigen | 2 | 2023 | 283 | 0.100 |
Why?
|
Young Adult | 12 | 2024 | 58755 | 0.100 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2021 | 1896 | 0.100 |
Why?
|
Walking | 1 | 2019 | 1190 | 0.100 |
Why?
|
Life Style | 3 | 2021 | 3886 | 0.100 |
Why?
|
RNA, Small Interfering | 1 | 2021 | 3432 | 0.100 |
Why?
|
Child Mortality | 1 | 2014 | 205 | 0.100 |
Why?
|
Medication Therapy Management | 1 | 2013 | 130 | 0.100 |
Why?
|
Health Services Needs and Demand | 2 | 2021 | 1398 | 0.100 |
Why?
|
Social Class | 1 | 2020 | 1996 | 0.100 |
Why?
|
Uncertainty | 1 | 2016 | 750 | 0.090 |
Why?
|
Age Factors | 5 | 2020 | 18326 | 0.090 |
Why?
|
Maternal Mortality | 1 | 2014 | 299 | 0.090 |
Why?
|
Insurance Coverage | 2 | 2019 | 1919 | 0.090 |
Why?
|
Pneumonia | 2 | 2019 | 2127 | 0.090 |
Why?
|
Coronary Thrombosis | 1 | 2014 | 440 | 0.090 |
Why?
|
Drug Prescriptions | 2 | 2017 | 1666 | 0.090 |
Why?
|
Air Pollution | 1 | 2024 | 2314 | 0.090 |
Why?
|
Venous Thromboembolism | 1 | 2023 | 1847 | 0.090 |
Why?
|
Diarrhea | 1 | 2017 | 1317 | 0.090 |
Why?
|
Tachycardia, Ectopic Atrial | 1 | 2010 | 65 | 0.090 |
Why?
|
Quality Indicators, Health Care | 1 | 2020 | 1791 | 0.090 |
Why?
|
Heart | 1 | 2023 | 4382 | 0.090 |
Why?
|
Hospitals | 1 | 2023 | 3861 | 0.090 |
Why?
|
Natural Language Processing | 1 | 2018 | 1135 | 0.090 |
Why?
|
Fever | 1 | 2017 | 1617 | 0.080 |
Why?
|
Thrombosis | 1 | 2023 | 2931 | 0.080 |
Why?
|
Models, Cardiovascular | 1 | 2015 | 970 | 0.080 |
Why?
|
Health Resources | 1 | 2016 | 931 | 0.080 |
Why?
|
User-Computer Interface | 1 | 2016 | 1397 | 0.080 |
Why?
|
Thiophenes | 1 | 2014 | 569 | 0.080 |
Why?
|
Infant Mortality | 1 | 2014 | 757 | 0.080 |
Why?
|
Cardiac Complexes, Premature | 1 | 2008 | 63 | 0.080 |
Why?
|
Stents | 1 | 2021 | 3162 | 0.080 |
Why?
|
Coronary Vessels | 1 | 2020 | 3072 | 0.080 |
Why?
|
Metabolic Diseases | 1 | 2015 | 681 | 0.080 |
Why?
|
Guidelines as Topic | 1 | 2015 | 1384 | 0.080 |
Why?
|
World Health Organization | 1 | 2014 | 1312 | 0.080 |
Why?
|
Coronary Angiography | 1 | 2020 | 4451 | 0.080 |
Why?
|
Heart Ventricles | 1 | 2020 | 3806 | 0.080 |
Why?
|
Ambulatory Care | 2 | 2016 | 2767 | 0.080 |
Why?
|
Adolescent | 10 | 2021 | 87819 | 0.080 |
Why?
|
Organizational Objectives | 3 | 2014 | 426 | 0.080 |
Why?
|
Calcium | 2 | 2020 | 5720 | 0.080 |
Why?
|
Incidence | 8 | 2021 | 21217 | 0.080 |
Why?
|
Adrenal Cortex Hormones | 1 | 2017 | 1870 | 0.080 |
Why?
|
Time Factors | 8 | 2022 | 39811 | 0.070 |
Why?
|
Patient Compliance | 1 | 2017 | 2685 | 0.070 |
Why?
|
Occupational Diseases | 1 | 2015 | 1487 | 0.070 |
Why?
|
Patient Selection | 2 | 2013 | 4235 | 0.070 |
Why?
|
Prospective Studies | 7 | 2024 | 54092 | 0.070 |
Why?
|
Louisiana | 1 | 2006 | 103 | 0.070 |
Why?
|
Cardiac Resynchronization Therapy | 1 | 2013 | 553 | 0.070 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2021 | 3970 | 0.070 |
Why?
|
Longitudinal Studies | 3 | 2020 | 14473 | 0.070 |
Why?
|
Internship and Residency | 1 | 2006 | 5854 | 0.070 |
Why?
|
Prognosis | 6 | 2022 | 29488 | 0.070 |
Why?
|
Ultrasonography | 1 | 2019 | 5951 | 0.070 |
Why?
|
Blood Pressure Determination | 2 | 2020 | 634 | 0.070 |
Why?
|
Wounds and Injuries | 1 | 2018 | 2475 | 0.070 |
Why?
|
Critical Illness | 1 | 2018 | 2705 | 0.060 |
Why?
|
Sanitation | 2 | 2016 | 85 | 0.060 |
Why?
|
Uganda | 2 | 2021 | 1324 | 0.060 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2010 | 706 | 0.060 |
Why?
|
Texas | 1 | 2006 | 402 | 0.060 |
Why?
|
Developing Countries | 2 | 2015 | 2865 | 0.060 |
Why?
|
Acute Disease | 1 | 2016 | 7225 | 0.060 |
Why?
|
Research Design | 1 | 2021 | 6152 | 0.060 |
Why?
|
Health Policy | 1 | 2017 | 2674 | 0.060 |
Why?
|
Child | 6 | 2023 | 79782 | 0.060 |
Why?
|
Echocardiography | 3 | 2022 | 4963 | 0.060 |
Why?
|
Diagnosis, Differential | 1 | 2020 | 12951 | 0.060 |
Why?
|
Altruism | 1 | 2006 | 205 | 0.060 |
Why?
|
Lung | 2 | 2020 | 9973 | 0.060 |
Why?
|
Malaria | 1 | 2014 | 1224 | 0.060 |
Why?
|
Age Distribution | 3 | 2015 | 2877 | 0.060 |
Why?
|
Narration | 1 | 2006 | 219 | 0.060 |
Why?
|
Body Mass Index | 1 | 2022 | 12868 | 0.060 |
Why?
|
Renal Insufficiency, Chronic | 2 | 2020 | 2237 | 0.060 |
Why?
|
Electronic Health Records | 2 | 2018 | 4760 | 0.060 |
Why?
|
Hospitalization | 5 | 2021 | 10634 | 0.060 |
Why?
|
Apolipoprotein A-I | 1 | 2005 | 294 | 0.060 |
Why?
|
Drug Evaluation | 1 | 2005 | 642 | 0.050 |
Why?
|
Polymorphism, Genetic | 1 | 2014 | 4282 | 0.050 |
Why?
|
Piperazines | 1 | 2014 | 2511 | 0.050 |
Why?
|
Quality of Health Care | 2 | 2016 | 4307 | 0.050 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2007 | 12078 | 0.050 |
Why?
|
Physician-Patient Relations | 1 | 2016 | 3238 | 0.050 |
Why?
|
Product Surveillance, Postmarketing | 1 | 2007 | 452 | 0.050 |
Why?
|
Alleles | 1 | 2014 | 6894 | 0.050 |
Why?
|
Sex Factors | 3 | 2019 | 10495 | 0.050 |
Why?
|
Health Services Research | 2 | 2020 | 1811 | 0.050 |
Why?
|
American Dental Association | 1 | 2021 | 16 | 0.050 |
Why?
|
Meta-Analysis as Topic | 1 | 2007 | 1373 | 0.050 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2017 | 3217 | 0.050 |
Why?
|
Heroin | 1 | 2022 | 119 | 0.050 |
Why?
|
Empathy | 1 | 2006 | 472 | 0.050 |
Why?
|
Communication | 1 | 2016 | 3841 | 0.050 |
Why?
|
Severity of Illness Index | 2 | 2018 | 15781 | 0.050 |
Why?
|
Tuberculosis | 1 | 2014 | 2001 | 0.050 |
Why?
|
Penicillin G Benzathine | 1 | 2020 | 25 | 0.050 |
Why?
|
Oligonucleotides | 1 | 2024 | 582 | 0.050 |
Why?
|
Monte Carlo Method | 2 | 2017 | 1256 | 0.050 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2020 | 10749 | 0.040 |
Why?
|
Medication Adherence | 3 | 2017 | 2155 | 0.040 |
Why?
|
Renin-Angiotensin System | 1 | 2005 | 733 | 0.040 |
Why?
|
Kidney Failure, Chronic | 1 | 2012 | 2455 | 0.040 |
Why?
|
Schools, Medical | 1 | 2006 | 877 | 0.040 |
Why?
|
Prisons | 1 | 2022 | 174 | 0.040 |
Why?
|
Clinical Competence | 1 | 2015 | 4760 | 0.040 |
Why?
|
Sex Distribution | 2 | 2015 | 2278 | 0.040 |
Why?
|
Risk | 2 | 2021 | 9590 | 0.040 |
Why?
|
Accidents, Aviation | 1 | 2018 | 15 | 0.040 |
Why?
|
Colorado | 1 | 2019 | 165 | 0.040 |
Why?
|
Heart Transplantation | 1 | 2013 | 3220 | 0.040 |
Why?
|
Florida | 1 | 2020 | 425 | 0.040 |
Why?
|
Wit and Humor as Topic | 1 | 2018 | 31 | 0.040 |
Why?
|
Pentoxifylline | 1 | 1999 | 53 | 0.040 |
Why?
|
United States Food and Drug Administration | 1 | 2007 | 1658 | 0.040 |
Why?
|
Poverty | 2 | 2021 | 2685 | 0.040 |
Why?
|
Genetic Testing | 2 | 2022 | 3529 | 0.040 |
Why?
|
Health Behavior | 2 | 2024 | 2613 | 0.040 |
Why?
|
History, 21st Century | 1 | 2024 | 1568 | 0.040 |
Why?
|
Hypercalcemia | 1 | 2001 | 421 | 0.040 |
Why?
|
Sodium Channel Blockers | 1 | 2019 | 172 | 0.040 |
Why?
|
Aircraft | 1 | 2018 | 125 | 0.040 |
Why?
|
International Cooperation | 1 | 2024 | 1428 | 0.040 |
Why?
|
Phosphodiesterase Inhibitors | 1 | 1999 | 213 | 0.040 |
Why?
|
New York | 1 | 2020 | 873 | 0.040 |
Why?
|
Obesity | 3 | 2024 | 12870 | 0.040 |
Why?
|
Kenya | 1 | 2020 | 749 | 0.040 |
Why?
|
Models, Economic | 1 | 2021 | 715 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 1 | 2020 | 20499 | 0.030 |
Why?
|
Macrophages, Alveolar | 1 | 1999 | 409 | 0.030 |
Why?
|
History, 20th Century | 1 | 2024 | 2769 | 0.030 |
Why?
|
Probability | 1 | 2021 | 2462 | 0.030 |
Why?
|
Bioprosthesis | 1 | 2020 | 591 | 0.030 |
Why?
|
Health Planning Organizations | 1 | 2015 | 13 | 0.030 |
Why?
|
Length of Stay | 2 | 2019 | 6384 | 0.030 |
Why?
|
Vesico-Ureteral Reflux | 1 | 2019 | 437 | 0.030 |
Why?
|
Diagnosis | 1 | 2016 | 156 | 0.030 |
Why?
|
Injury Severity Score | 1 | 2018 | 1032 | 0.030 |
Why?
|
Delayed-Action Preparations | 1 | 2019 | 961 | 0.030 |
Why?
|
Child, Preschool | 4 | 2021 | 42045 | 0.030 |
Why?
|
Ventricular Remodeling | 1 | 2022 | 1256 | 0.030 |
Why?
|
International Classification of Diseases | 1 | 2020 | 891 | 0.030 |
Why?
|
Reproducibility of Results | 3 | 2020 | 20037 | 0.030 |
Why?
|
Gross Domestic Product | 1 | 2014 | 78 | 0.030 |
Why?
|
Vasodilator Agents | 1 | 2019 | 973 | 0.030 |
Why?
|
Insecticide-Treated Bednets | 1 | 2014 | 68 | 0.030 |
Why?
|
Lactic Acid | 1 | 1999 | 1133 | 0.030 |
Why?
|
Tuberculosis, Pulmonary | 1 | 2001 | 831 | 0.030 |
Why?
|
Survival Rate | 2 | 2022 | 12684 | 0.030 |
Why?
|
Urban Population | 1 | 2022 | 2023 | 0.030 |
Why?
|
Ambulatory Care Facilities | 1 | 2020 | 927 | 0.030 |
Why?
|
Accidents, Traffic | 1 | 2019 | 815 | 0.030 |
Why?
|
Predictive Value of Tests | 2 | 2019 | 15207 | 0.030 |
Why?
|
Urinary Bladder | 1 | 2019 | 1148 | 0.030 |
Why?
|
Health Care Surveys | 1 | 2020 | 2425 | 0.030 |
Why?
|
Thrombolytic Therapy | 1 | 2022 | 2060 | 0.030 |
Why?
|
Databases, Factual | 2 | 2020 | 7927 | 0.030 |
Why?
|
Antitubercular Agents | 1 | 2001 | 1373 | 0.030 |
Why?
|
Infant | 3 | 2021 | 36045 | 0.030 |
Why?
|
Kaplan-Meier Estimate | 2 | 2013 | 6470 | 0.030 |
Why?
|
Syphilis | 1 | 2014 | 243 | 0.020 |
Why?
|
Safety | 1 | 2016 | 1147 | 0.020 |
Why?
|
Geriatric Assessment | 1 | 2019 | 1402 | 0.020 |
Why?
|
Animals | 2 | 2019 | 167718 | 0.020 |
Why?
|
Blood Vessel Prosthesis Implantation | 1 | 2022 | 1427 | 0.020 |
Why?
|
Health Priorities | 1 | 2014 | 374 | 0.020 |
Why?
|
Focus Groups | 1 | 2016 | 1380 | 0.020 |
Why?
|
Linear Models | 1 | 2021 | 5856 | 0.020 |
Why?
|
Office Visits | 1 | 2015 | 594 | 0.020 |
Why?
|
Socioeconomic Factors | 2 | 2014 | 7796 | 0.020 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2019 | 1181 | 0.020 |
Why?
|
Liver | 1 | 2005 | 7502 | 0.020 |
Why?
|
Peripheral Arterial Disease | 1 | 2020 | 1246 | 0.020 |
Why?
|
Refractory Period, Electrophysiological | 1 | 2008 | 39 | 0.020 |
Why?
|
Patient Satisfaction | 1 | 2021 | 3440 | 0.020 |
Why?
|
Life Expectancy | 1 | 2015 | 1238 | 0.020 |
Why?
|
Chronic Disease | 1 | 2023 | 9263 | 0.020 |
Why?
|
Alcoholism | 1 | 2019 | 1965 | 0.020 |
Why?
|
Benchmarking | 1 | 2014 | 1041 | 0.020 |
Why?
|
Endovascular Procedures | 1 | 2022 | 2140 | 0.020 |
Why?
|
Disease Progression | 1 | 2005 | 13463 | 0.020 |
Why?
|
Infant, Newborn | 2 | 2021 | 26176 | 0.020 |
Why?
|
Disability Evaluation | 1 | 2015 | 1825 | 0.020 |
Why?
|
Public Health | 1 | 2021 | 2658 | 0.020 |
Why?
|
Analgesics, Opioid | 1 | 2023 | 3762 | 0.020 |
Why?
|
Massachusetts | 1 | 2020 | 8815 | 0.020 |
Why?
|
Nutritional Status | 1 | 2015 | 1606 | 0.020 |
Why?
|
Single-Blind Method | 1 | 2010 | 1567 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2019 | 12047 | 0.020 |
Why?
|
Decision Support Systems, Clinical | 1 | 2015 | 1159 | 0.020 |
Why?
|
Guideline Adherence | 1 | 2016 | 2212 | 0.020 |
Why?
|
Diet | 1 | 2024 | 8001 | 0.020 |
Why?
|
Propensity Score | 1 | 2013 | 1886 | 0.020 |
Why?
|
Intensive Care Units | 1 | 2018 | 3732 | 0.020 |
Why?
|
Case-Control Studies | 2 | 2019 | 22022 | 0.020 |
Why?
|
Occupational Exposure | 1 | 2015 | 1810 | 0.020 |
Why?
|
Anti-Retroviral Agents | 1 | 2014 | 1780 | 0.020 |
Why?
|
Logistic Models | 1 | 2019 | 13221 | 0.020 |
Why?
|
Kidney | 1 | 2019 | 7012 | 0.010 |
Why?
|
Cytokines | 1 | 1999 | 7336 | 0.010 |
Why?
|
Disease Management | 1 | 2014 | 2495 | 0.010 |
Why?
|
Pulmonary Veins | 1 | 2008 | 745 | 0.010 |
Why?
|
Pregnancy | 2 | 2014 | 29712 | 0.010 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2014 | 2125 | 0.010 |
Why?
|
Action Potentials | 1 | 2008 | 1816 | 0.010 |
Why?
|
Greece | 1 | 2001 | 336 | 0.010 |
Why?
|
Survival Analysis | 1 | 2013 | 10075 | 0.010 |
Why?
|
Mutation | 1 | 2005 | 29929 | 0.010 |
Why?
|
Respiratory Care Units | 1 | 1999 | 10 | 0.010 |
Why?
|
Emergency Service, Hospital | 1 | 2019 | 7798 | 0.010 |
Why?
|
Depression, Chemical | 1 | 1999 | 184 | 0.010 |
Why?
|
Pyruvic Acid | 1 | 1999 | 195 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2013 | 12397 | 0.010 |
Why?
|
Comorbidity | 1 | 2013 | 10477 | 0.010 |
Why?
|
Physicians | 1 | 2016 | 4577 | 0.010 |
Why?
|
Albumins | 1 | 2001 | 575 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2020 | 15532 | 0.010 |
Why?
|
Cell Hypoxia | 1 | 1999 | 656 | 0.010 |
Why?
|
Bronchoalveolar Lavage Fluid | 1 | 1999 | 748 | 0.010 |
Why?
|
Macrophage Activation | 1 | 1999 | 552 | 0.010 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1999 | 886 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2010 | 14637 | 0.010 |
Why?
|
Interleukin-1 | 1 | 1999 | 1249 | 0.010 |
Why?
|
Leukocytes, Mononuclear | 1 | 1999 | 1825 | 0.010 |
Why?
|
Lipopolysaccharides | 1 | 1999 | 2203 | 0.010 |
Why?
|
Hemodynamics | 1 | 1999 | 4156 | 0.010 |
Why?
|
Interleukin-6 | 1 | 1999 | 3206 | 0.000 |
Why?
|
Protein Binding | 1 | 2001 | 9312 | 0.000 |
Why?
|
Lung Diseases | 1 | 1999 | 1908 | 0.000 |
Why?
|
Respiration, Artificial | 1 | 1999 | 2619 | 0.000 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 1999 | 4338 | 0.000 |
Why?
|
Cells, Cultured | 1 | 1999 | 18936 | 0.000 |
Why?
|